National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
Tropical and Infectious Diseases Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
PLoS One. 2022 Jun 2;17(6):e0263595. doi: 10.1371/journal.pone.0263595. eCollection 2022.
Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome.
We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models.
We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67-82]), than encephalopathy (54% [42-65]). Intensive care use was high (38% [35-41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27-32]. The hazard of death was comparatively lower for patients in the WHO European region.
Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.
新冠病毒相关神经系统疾病已被广泛报道,但已发表的研究常缺乏有关神经系统结局和预后危险因素的信息。本研究旨在描述住院新冠病毒患者的神经系统疾病谱;描述临床结局;并探讨与不良结局相关的因素。
我们对住院新冠病毒神经系统疾病患者的个体患者数据(IPD)进行了荟萃分析,使用了标准的病例定义。我们邀请了第一波大流行期间研究的作者,以及全球新冠病毒神经网络中有未发表数据的临床医生,来提供 IPD。我们使用多变量模型分析了与不良结局(改良 Rankin 量表 3-6 分的中重度残疾或死亡)相关的特征。
我们纳入了 83 项研究(31 项未发表),提供了 1979 例新冠病毒急性新发神经系统疾病患者的 IPD。脑病(978 例[49%]患者)和脑血管事件(506 例[26%]患者)是最常见的诊断。93%的患者在出现神经系统表现之前有呼吸道和全身症状;三分之一的患者在住院后出现神经系统疾病。脑血管事件患者的不良结局更为常见(76%[67-82]),而脑病患者为 54%(42-65)。总体而言,重症监护使用率较高(38%[35-41]),脑血管事件患者更高。在脑血管病患者中,但不是脑病患者中,不良结局的危险因素包括入院时呼吸困难和 D-二聚体升高。总体而言,30 天死亡率为 30%(27-32)。来自世卫组织欧洲区域的患者死亡风险相对较低。
新冠病毒相关神经系统疾病在疾病结局和对延长重症监护和住院治疗的医院资源的使用方面造成了相当大的负担;初步数据表明,这些可能因世卫组织区域和国家收入水平而异。脑病和中风的不同危险因素提示不同的疾病机制,这些机制可能可以干预,特别是对于那些在住院后出现神经系统症状的患者。